BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
Location: Sweden, Lund
Employees: 51-200
Total raised: $53.26M
Investors 3
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | Forbion | forbion.co... |
| - | Ideon Scie... | ideon.se |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.06.2020 | - | $53.26M | - |
Mentions in press and media 32
| Date | Title | Description | Source |
| 30.04.2024 | BioInvent evaluating Attana Technology | BioInvent evaluating Attana Technology Tue, Apr 30, 2024 11:45 CET Report this content BioInvent and... | news.cisio... |
| 11.03.2024 | BioStock: BioInvent’s CEO comments on the study success in C... | BioStock: BioInvent’s CEO comments on the study success in China Mon, Mar 11, 2024 12:31 CET Report ... | news.cisio... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Sprin... | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! Mon, May 29, ... | news.cisio... |
| 31.01.2023 | Change in the Number of Shares and Votes in BioInvent Intern... | LUND, SE / ACCESSWIRE / January 31, 2023 / BioInvent International BINV Lund, Sweden, January 31, 20... | einpresswi... |
| 17.01.2023 | BioInvent Selected to The Leukemia & Lymphoma Society’s ... | Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgk... | accesswire... |
| 18.11.2022 | BioInvent Receives FDA IND Approval for Anti-FcyRIIB Antibod... | LUND, SE / ACCESSWIRE / November 18, 2022 / BioInvent International (STO:BINV) Phase 1/2a trial in c... | accesswire... |
| 25.08.2022 | BioInvent International AB: Interim Report January-June 2022 | LUND, SWEDEN / ACCESSWIRE / August 25, 2022 / BioInvent International (STO:BINV) "The second qu... | accesswire... |
| 29.07.2022 | Change in the Number of Shares and Votes in BioInvent Intern... | LUND, SWEDEN / ACCESSWIRE / July 29, 2022 / BioInvent International (STO:BINV) Lund, Sweden - July 2... | accesswire... |
| 16.06.2022 | Exelixis taps into cancer antibody discoverer out o... | Exelixis is doling out $25 million to snag rights to choose three targets found by BioInvent. ... | endpts.com... |
| 28.04.2022 | BioInvent Receives Milestone Payment from Bayer/Hope Medicin... | LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV) Lund, Sweden - April... | accesswire... |
Show more